Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia - Integrated data from 1 499 study participants

BJU International

Volumn 115, Issue 5, 2015, Pages 815-821

  Nickel, John Curtis ^a   Brock, Gerald B ^b   Herschorn, Sender ^c   Dickson, Ruth ^d   Henneges, Carsten ^e   Viktrup, Lars ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ELI LILLY AND COMPANY   (United States)

^e LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

benign prostatic hyperplasia; meaningful improvement; tadalafil

Indexed keywords

PLACEBO; TADALAFIL; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE FLOW RATE; COMPLICATION; DOUBLE BLIND PROCEDURE; LOWER URINARY TRACT SYMPTOMS; REMISSION;

CARBOLINES; DOUBLE-BLIND METHOD; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; REMISSION INDUCTION;

EID: 84927912672     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12926     Document Type: Article

References (22)

1. McVary KT,. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12: S122-8
2. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64: 118-40
3. Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 1105-13
4. Egerdie RB, Auerback S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results from a randomized, placebo-controlled double-blind study. J Sex Med 2012; 9: 271-81
5. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L,. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary symptoms suggestive of benign prostatic hyperplasia in an international, randomized, paralled, placebo-controlled clinical trial. Eur Urol 2012; 61: 917-25
6. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L,. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-34
7. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4
8. American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Guideline Update Panel. American Urological Association Guideline: management of Benign Prostatic Hyperplasia (BPH). American Urological Association. Revised March 2010. Available at: http://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm. Accessed November 2013
9. Lepor H,. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892-900
10. Narayan P, Tewari A, Members of the United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701-6
11. Chapple CR, Montorsi F, Tammela TL, et al. Sildosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011; 59: 342-52
12. Barry MJ, Fowler J, O'Leary MP, et al. The American Urological Association Symptom Index for benign protatic hyperplasia. J Urol 1992; 148: 1549-57
13. Revicki DA, Erickson PA, Sloan JA, Dueck A, Guess H, Santangello NC,. Interpreting and reporting results based on patient-reported outcomes. Value Health 2007; 10: S116-24
14. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Clinical Studies section of labeling for Human prescription drug and biological products-content and format. January 2006. Available at: http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm127534.pdf. Accessed November 2013
15. Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L,. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. BJU Int 2013; 112: 990-7
16. Brock GB, McVary KT, Roehrborn CG, et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 2014; 191: 405-11
17. van Leeuwen JH, Castro R, Busse M, Bemelmans BL,. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50: 440-53
18. Nickel JC,. Placebo therapy of benign prostatic hyperplasia: a 25 month study. Br J Urol 1998; 81: 383-7
19. Hansen BJ, Meyhoff HH, Nordling J, et al. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. Scand J Urol Nephrol 1996; 30: 373-7
20. Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: randomized controlled trial. BMJ 2007; 334: 25-8
21. Roehrborn CG, Chapple C, Oelke M, Cox D, Esler A, Viktrup L,. Effects of tadalafil once daily on the maximum flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol 2014; 191: 1045-50
22. Porst H, Oelke M, Goldfischer ER, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 2013; 82: 667-73